JP2011522795A5 - - Google Patents

Download PDF

Info

Publication number
JP2011522795A5
JP2011522795A5 JP2011508582A JP2011508582A JP2011522795A5 JP 2011522795 A5 JP2011522795 A5 JP 2011522795A5 JP 2011508582 A JP2011508582 A JP 2011508582A JP 2011508582 A JP2011508582 A JP 2011508582A JP 2011522795 A5 JP2011522795 A5 JP 2011522795A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
molecule
composition according
region
ctla4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011508582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011522795A (ja
Filing date
Publication date
Priority claimed from US12/387,359 external-priority patent/US7915222B2/en
Application filed filed Critical
Publication of JP2011522795A publication Critical patent/JP2011522795A/ja
Publication of JP2011522795A5 publication Critical patent/JP2011522795A5/ja
Pending legal-status Critical Current

Links

JP2011508582A 2008-05-05 2009-05-05 未分類関節炎を有する対象における関節リウマチの発症を予防するための方法 Pending JP2011522795A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5033608P 2008-05-05 2008-05-05
US61/050,336 2008-05-05
US12/387,359 2009-05-01
US12/387,359 US7915222B2 (en) 2008-05-05 2009-05-01 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
PCT/US2009/042761 WO2009137424A1 (en) 2008-05-05 2009-05-05 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Publications (2)

Publication Number Publication Date
JP2011522795A JP2011522795A (ja) 2011-08-04
JP2011522795A5 true JP2011522795A5 (https=) 2012-03-15

Family

ID=41264941

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011508582A Pending JP2011522795A (ja) 2008-05-05 2009-05-05 未分類関節炎を有する対象における関節リウマチの発症を予防するための方法

Country Status (25)

Country Link
US (3) US7915222B2 (https=)
EP (2) EP2279206B1 (https=)
JP (1) JP2011522795A (https=)
KR (1) KR20110014180A (https=)
CN (1) CN102037010A (https=)
AR (1) AR071672A1 (https=)
AU (1) AU2009244448B2 (https=)
BR (1) BRPI0912249A2 (https=)
CA (1) CA2723698C (https=)
CL (1) CL2009001082A1 (https=)
DK (1) DK2279206T3 (https=)
EA (1) EA201001749A1 (https=)
ES (1) ES2539840T3 (https=)
HK (1) HK1208230A1 (https=)
HR (1) HRP20150552T1 (https=)
HU (1) HUE025256T2 (https=)
IL (1) IL208691A (https=)
MX (1) MX2010011503A (https=)
NZ (1) NZ589020A (https=)
PL (1) PL2279206T3 (https=)
PT (1) PT2279206E (https=)
SI (1) SI2279206T1 (https=)
TW (2) TW201444575A (https=)
WO (1) WO2009137424A1 (https=)
ZA (1) ZA201007914B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
EP2766394B1 (en) * 2011-10-10 2017-11-22 Medimmune Limited Treatment for rheumatoid arthritis
US20140006055A1 (en) * 2012-06-27 2014-01-02 Iagnosis, Inc. Integrated Medical Evaluation and Record Keeping System
EP2914292A4 (en) * 2012-10-30 2016-05-04 Univ Emory Stimulation of bone formation by inhibition of CD28-co-stimulation
WO2014151230A2 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Method of treating granulomatosis with polyangiitis
KR20160145789A (ko) * 2014-04-25 2016-12-20 브리스톨-마이어스 스큅 컴퍼니 초기 ra를 갖는 대상체에서의 무약물 완화를 달성하기 위한 ctla4 화합물의 용도
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
CN110148465B (zh) * 2019-05-10 2023-07-04 中山大学孙逸仙纪念医院 一种用于分析类风湿性关节炎的系统

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US7070776B1 (en) 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
DE69226871T3 (de) 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
CA2154487A1 (en) * 1993-01-21 1994-08-04 Nicholas S. Hill Vaccines and methods for preventing and treating fescue toxicosis in herbivores
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
IL125928A (en) 1996-03-20 2002-11-10 Bristol Myers Squibb Co The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations
ZA98533B (en) 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
WO2001095928A2 (en) 2000-06-09 2001-12-20 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
SI1372696T1 (sl) 2000-07-03 2008-12-31 Bristol Myers Squibb Co Metoda za zdravljenje revmatskih bolezni z uporabo topne molekule ctla4
AU2002243905B2 (en) 2001-01-26 2007-11-08 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
MXPA03010568A (es) 2001-05-23 2005-03-07 Squibb Bristol Myers Co Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
CN101857851A (zh) 2002-12-23 2010-10-13 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
DE60335024D1 (de) 2002-12-23 2010-12-30 Bristol Myers Squibb Co Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
CA2762015A1 (en) 2003-08-04 2005-02-24 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble ctla4 molecule
KR101280096B1 (ko) 2005-06-29 2013-06-28 컴퓨메딕스 리미티드 전도성 브리지를 포함하는 센서 어셈블리
CA2619429A1 (en) * 2005-08-22 2007-03-01 Incept, Llc Flared stents and apparatus and methods for making and using them
EP2253644B1 (en) 2005-12-20 2013-10-16 Bristol-Myers Squibb Company Compositions and methods for producing a composition
CN101584858A (zh) 2005-12-20 2009-11-25 布里斯托尔-迈尔斯斯奎布公司 稳定蛋白质制剂
US7528111B2 (en) 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Similar Documents

Publication Publication Date Title
JP2011522795A5 (https=)
RU2571204C3 (ru) Специфические связывающие агенты против в7-н1
HRP20150552T1 (hr) Metoda za sprjeäśavanje razvoja reumatoidnog artritisa kod podložnih osoba s nediferenciranim artritisom
JP2010511388A5 (https=)
JP2010529957A5 (https=)
FI3415531T3 (fi) Bcma:aa (cd269/tnfrsf17) sitovia proteiineja
JP2014502955A5 (https=)
JP2014039548A5 (https=)
JP2019510739A5 (https=)
CN110740754A (zh) 一种抗间皮素抗体及其抗体药物缀合物
HRP20140604T1 (hr) Sredstva koja djeluju na cd138 i njihova upotreba
JP2015508757A5 (https=)
JP2017528419A5 (https=)
JP2010500005A5 (https=)
NZ603623A (en) Tcr complex immunotherapeutics
JP2004248677A5 (https=)
JP2012500020A5 (https=)
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
JP2019507589A5 (https=)
PE20131334A1 (es) Anticuerpo igg1 humanizado
ME00519B (me) Antitijela visokog afiniteta prema humanom il-6 receptoru
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
JP2011524420A5 (https=)
JP2017500018A5 (https=)
JP2016512213A5 (https=)